Merseyside Inter Agency Drug Misuse Database

January - March 2009

St Helens DAAT

Quarter 4 2008/09

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

National Drug Treatment Monitoring System (NDTMS) 14

Connexions 17

Combined Datasets 19

Cross Matched Datasets 20

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2008/09)

Introduction
Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	98	89.1
Female	12	10.9
Age Group		
Under 18	0	0.0
18-19	8	7.3
20-24	31	28.2
25-29	26	23.6
30-34	14	12.7
35-39	18	16.4
40-44	9	8.2
45+	4	3.6
Total	110	100

Table 2: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	16	6.0	3	6.8	19	6.1
20-24	76	28.5	4	9.1	80	25.7
25-29	53	19.9	10	22.7	63	20.3
30-34	36	13.5	11	25.0	47	15.1
35-39	44	16.5	8	18.2	52	16.7
40-44	26	9.7	5	11.4	31	10.0
45+	16	6.0	3	6.8	19	6.1
Total	267	100	44	100	311	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	1
Benzodiazepines	1	1
Cannabis	15	10
Crack	11	5
Cocaine	9	17
Ecstasy	0	0
Heroin	32	4
Methadone	1	3
Other	2	1

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES
Quarter 4 (2008/09)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	73	89.0
Female	9	11.0
Total	82	100
All Clients		
Male	373	87.4
Female	54	12.6
Total	427	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	19	70.4
Female	8	29.6
Total	27	100
All Clients		
Male	226	81.0
Female	53	19.0
Total	279	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	1	<1
18-19	6	7.3	11	2.6
20-24	21	25.6	57	13.3
25-29	19	23.2	87	20.4
30-34	12	14.6	69	16.2
35-39	16	19.5	99	23.2
40-44	5	6.1	61	14.3
45+	3	3.7	42	9.8
Total	82	100	427	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	1	<1
20-24	3	11.1	14	5.0
25-29	5	18.5	43	15.4
30-34	5	18.5	47	16.8
35-39	9	33.3	82	29.4
40-44	3	11.1	55	19.7
45+	2	7.4	37	13.3
Total	27	100	279	100

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	1	<1	0	0.0
18-19	11	2.9	0	0.0
20-24	49	13.1	8	14.8
25-29	74	19.8	13	24.1
30-34	60	16.1	9	16.7
35-39	85	22.8	14	25.9
40-44	56	15.0	5	9.3
45+	37	9.9	5	9.3
Total	373	100	54	100

Table 9: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	<1	0	0.0
20-24	6	2.7	8	15.1
25-29	31	13.7	12	22.6
30-34	38	16.8	9	17.0
35-39	68	30.1	14	26.4
40-44	50	22.1	5	9.4
45+	32	14.2	5	9.4
Total	226	100	53	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	<1	0	0.0	1	<1
18-19	20	2.8	0	0.0	20	2.5
20-24	100	14.2	14	15.7	114	14.4
25-29	145	20.6	18	20.2	163	20.6
30-34	118	16.8	24	27.0	142	17.9
35-39	167	23.7	20	22.5	187	23.6
40-44	90	12.8	7	7.9	97	12.2
45+	63	8.9	6	6.7	69	8.7
Total	704	100	89	100	793	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	<1	0	0.0	1	<1
20-24	19	4.5	14	16.1	33	6.5
25-29	59	13.9	17	19.5	76	14.9
30-34	75	17.7	24	27.6	99	19.4
35-39	136	32.1	19	21.8	155	30.3
40-44	78	18.4	7	8.0	85	16.6
45+	56	13.2	6	6.9	62	12.1
Total	424	100	87	100	511	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	15	20.0	6	60.0
Methadone	1	1.3	0	0.0
Melanotan	2	2.7	1	10.0
Steroids	54	72.0	1	10.0
Other	3	4.0	2	20.0
Total	75	100	10	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for All Agency Syringe Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Amphetamines	14	3.7	1	1.8
Benzodiazepines	0	0.0	0	0.0
Cocaine	2	<1	0	0.0
Crack	0	0.0	0	0.0
Heroin	154	40.3	38	67.9
Methadone	29	7.6	10	17.9
Melanotan	9	2.4	2	3.6
Steroids	147	38.5	1	1.8
Other	27	7.0	4	7.1
*Total**	382	100	56	100

*Please Note: Totals may not be concurrent due to the reporting of Melanotan clients. Further details are available on request.

Table 14: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	0	0.0	0	0.0
18-19	-	-	-	-	-	-	-	-	0	0.0	0	0.0	6	10.9
20-24	-	-	-	-	-	-	-	-	2	9.5	0	0.0	18	32.7
25-29	-	-	-	-	-	-	-	-	5	23.8	0	0.0	14	25.5
30-34	-	-	-	-	-	-	-	-	4	19.0	0	0.0	7	12.7
35-39	-	-	-	-	-	-	-	-	6	28.6	1	100	7	12.7
40-44	-	-	-	-	-	-	-	-	2	9.5	0	0.0	2	3.6
45+	-	-	-	-	-	-	-	-	2	9.5	0	0.0	1	1.8
Total*	-	-	-	-	-	-	-	-	21	100	1	100	55	100

* % Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY SYRINGE EXCHANGE

Table 15: Individuals by Gender

New Clients	n	%
Male	61	81.3
Female	14	18.7
Total	75	100
All Clients		
Male	132	83.5
Female	26	16.5
Total	158	100

Table 16: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	2.7	3	1.9
20-24	7	9.3	15	9.5
25-29	17	22.7	40	25.3
30-34	18	24.0	37	23.4
35-39	21	28.0	37	23.4
40-44	6	8.0	16	10.1
45+	4	5.3	10	6.3
Total	75	100	158	100

Table 17: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	1	< 1	0	0.0	1	< 1
18-19	11	2.4	2	2.4	13	2.4
20-24	49	10.5	15	18.1	64	11.6
25-29	91	19.4	22	26.5	113	20.5
30-34	117	25.0	19	22.9	136	24.7
35-39	114	24.4	16	19.3	130	23.6
40-44	50	10.7	5	6.0	55	10.0
45+	35	7.5	4	4.8	39	7.1
Total	468	100	83	100	551	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 18: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	123	86.0
Female	20	14.0
Total	143	100
All Clients		
Male	465	86.8
Female	71	13.2
Total	536	100

Table 19: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	69	78.4
Female	19	21.6
Total	88	100
All Clients		
Male	318	82.0
Female	70	18.0
Total	388	100

*Only known steroid users, based on Agency SES data, have been omitted.

Table 20: Individuals in Syringe Exchange, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	1	< 1
18-19	7	4.9	13	2.4
20-24	27	18.9	65	12.1
25-29	34	23.8	114	21.3
30-34	27	18.9	94	17.5
35-39	33	23.1	127	23.7
40-44	8	5.6	70	13.1
45+	7	4.9	52	9.7
Total	143	100	536	100

Table 21: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	1.1	3	< 1
20-24	9	10.2	22	5.7
25-29	20	22.7	70	18.0
30-34	20	22.7	72	18.6
35-39	26	29.5	110	28.4
40-44	6	6.8	64	16.5
45+	6	6.8	47	12.1
Total	88	100	388	100

Table 22: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	< 1	0	0.0	2	< 1
18-19	33	3.1	1	< 1	34	2.8
20-24	141	13.3	26	18.3	167	13.9
25-29	211	19.9	32	22.5	243	20.2
30-34	215	20.3	38	26.8	253	21.0
35-39	243	22.9	26	18.3	269	22.4
40-44	121	11.4	9	6.3	130	10.8
45+	94	8.9	10	7.0	104	8.7
Total	1,060	100	142	100	1,202	100

Table 23: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	20,853	2,137	22,990	88,973

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2008/09)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 24: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	135	78.9
Female	36	21.1
Total	171	100
All Clients		
Male	933	75.7
Female	299	24.3
Total	1,232	100

Table 25: Year to Date, by Gender

New Clients	n	%
Male	425	76.2
Female	133	23.8
Total	558	100
All Clients		
Male	962	76.0
Female	304	24.0
Total	1,266	100

Table 26: Individuals in Contact with Treatment Services, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	11	6.4	117	9.5
18-19	1	<1	23	1.9
20-24	16	9.4	139	11.3
25-29	31	18.1	249	20.2
30-34	43	25.1	261	21.2
35-39	39	22.8	235	19.1
40-44	14	8.2	118	9.6
45+	16	9.4	90	7.3
Total	171	100	1,232	100

Table 27: Year to Date, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	61	10.9	117	9.2
18-19	11	2.0	24	1.9
20-24	63	11.3	143	11.3
25-29	104	18.6	261	20.6
30-34	122	21.9	269	21.2
35-39	104	18.6	239	18.9
40-44	54	9.7	123	9.7
45+	39	7.0	90	7.1
Total	558	100	1,266	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	170	99.4	1,220	99.0
White Irish	0	0.0	3	<1
Other White	0	0.0	2	<1
White & Black Caribbean	0	0.0	2	<1
White & Black African	0	0.0	1	<1
African	0	0.0	0	0.0
White & Asian	0	0.0	0	0.0
Other Black	0	0.0	0	0.0
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	0	0.0
Other	1	<1	4	<1
Unknown	0	0.0	0	0.0
Total	171	100	1,232	100

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	106	62.0	766	62.2
Methadone	10	5.8	75	6.1
Other Opiates	4	2.3	21	1.7
Benzodiazepine	1	<1	6	<1
Amphetamines	2	1.2	30	2.4
Cocaine	19	11.1	120	9.7
Crack	5	2.9	23	1.9
Ecstasy	0	0.0	5	<1
Cannabis	20	11.7	156	12.7
Prescription Drugs	1	<1	19	1.5
Other/Unknown	3	1.8	11	<1
Total	*171*	*100*	*1,232*	*100*

CONNEXIONS
Quarter 4 (2008/09)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 30: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	32	56.1
Female	25	43.9
Total	57	100

Table 31: Year to Date, by Gender

Gender	n	%
Male	44	58.7
Female	31	41.3
Total	75	100

Table 32: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	20	35.1
17	12	21.1
18	17	29.8
19	8	14.0
Total	57	100

Table 33: Year to Date, by Age

Age Group	n	%
16	24	32.0
17	14	18.7
18	21	28.0
19	16	21.3
Total	75	100

Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	18	31.6
Drugs	39	68.4
Total	57	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 35: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	26	34.7
Drugs	49	65.3
Total	75	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS
Quarter 4 (2008/09)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1,329	78.7
Female	360	21.3
Age Group		
Under 18	133	7.9
18-19	68	4.0
20-24	223	13.2
25-29	340	20.1
30-34	328	19.4
35-39	311	18.4
40-44	155	9.2
45+	131	7.8
Total	1,689	100

Table 37: Year to Date, by Gender and Age Group

|	Gender					
	Male		**Female**		*Total in Age Group*	
Age Group	n	%	n	%	*n*	%
Under 18	106	5.2	34	7.6	140	5.7
18-19	96	4.7	26	5.8	122	4.9
20-24	316	15.6	72	16.1	388	15.7
25-29	409	20.2	91	20.4	500	20.2
30-34	379	18.7	92	20.6	471	19.0
35-39	369	18.2	81	18.2	450	18.2
40-44	192	9.5	26	5.8	218	8.8
45+	160	7.9	24	5.4	184	7.4
Total	2,027	100	446	100	2,473	100

CROSS-MATCHED DATASETS
Quarter 4 (2008/09)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

AGENCY
(427)

159 Male
39 Female

NDTMS
(1,232)

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

PHARMACY
(158)

60 Male
12 Female

NDTMS
(1,232)